Relay Therapeutics to report Q2 2026 results on Aug 6
Relay Therapeutics, Inc. will announce Q2 2026 results on August 6, 2026. The clinical-stage firm develops precision medicines, including Phase 3 asset zovegalisib for breast cancer and genetic diseases. Investors await updates on financial health and pipeline progress.
*this image is generated using AI for illustrative purposes only.
Relay Therapeutics, Inc. (NASDAQ: RLAY) will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026. The announcement provides investors with an update on the clinical-stage company’s financial position and progress in developing precision medicine therapies for patients living with cancer and genetic disease.
The disclosure follows standard reporting timelines for publicly traded biotechnology firms. Relay Therapeutics operates as a small molecule precision medicine company, utilizing its Dynamo platform to target protein targets that have previously been intractable or inadequately addressed.
Pipeline Progress
The company’s lead clinical asset, zovegalisib, remains a central focus of its development efforts. Zovegalisib is the first pan-mutant selective PI3Kα inhibitor to enter clinical development. It is currently in a Phase 3 clinical trial, known as ReDiscover-2, for HR+/HER2- metastatic breast cancer.
In addition to oncology indications, zovegalisib is being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. The broader pipeline also includes programs targeting NRAS-driven solid tumors and Fabry disease.
Key Developments
| Asset | Indication | Stage | Details |
|---|---|---|---|
| Zovegalisib | HR+/HER2- metastatic breast cancer | Phase 3 | ReDiscover-2 trial |
| Zovegalisib | PI3Kα-driven vascular anomalies | Clinical | Genetic disease indication |
| Pipeline Assets | NRAS-driven solid tumors | Development | Small molecule program |
| Pipeline Assets | Fabry disease | Development | Small molecule program |
What This Means for Investors
For shareholders, the upcoming earnings release serves as a critical checkpoint for assessing the capital requirements and operational efficiency of Relay Therapeutics. As a clinical-stage entity, the company’s value is heavily tied to the successful progression of its late-stage assets like zovegalisib. Investors will likely scrutinize cash runway, burn rate, and any updates regarding the timeline for the ReDiscover-2 trial data readout or regulatory milestones.
The Dynamo platform’s ability to drug previously intractable targets underpins the company’s long-term growth thesis. Success in expanding the label for zovegalisib beyond breast cancer into genetic diseases could significantly enhance the asset’s commercial potential.
Contact Information
Investors and media seeking further details can contact Mitch Maisel at mmaisel@relaytx.com . Media inquiries are handled by Katie Engleman at 1AB, reachable at 919-333-7722 or katie@1abmedia.com .
How might Relay Therapeutics' cash runway and burn rate in Q2 2026 influence its need for additional capital raises before the ReDiscover-2 trial data readout?
What specific clinical endpoints or patient subgroups in the PI3Kα-driven vascular anomalies trials could serve as early indicators for zovegalisib's potential label expansion beyond oncology?
How does the progress of Relay's NRAS-driven solid tumor program compare to competitors targeting similar pathways, and what is the timeline for potential IND filings?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
